Literature DB >> 3079477

5-FU/leucovorin: biochemical modulation that works?

S G Arbuck1.   

Abstract

Three cooperative groups are currently accruing patients to randomized Phase III studies of 5-FU plus leucovorin. These studies should provide data allowing more definitive conclusions regarding the therapeutic utility of this combination. Until results of these studies are available, 5-FU plus leucovorin (CF) remains an investigational treatment, not suitable for routine use.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3079477

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  4 in total

1.  Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer.

Authors:  A Hageboutros; G R Hudes; F Greene; F P LaCreta; J Brennan; P J O'Dwyer
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 2.  Overview of chemotherapy for pancreatic cancer.

Authors:  S G Arbuck
Journal:  Int J Pancreatol       Date:  1990 Aug-Nov

3.  Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.

Authors:  A Hageboutros; A Rogatko; E M Newman; C McAleer; J Brennan; F P LaCreta; G R Hudes; R F Ozols; P J O'Dwyer
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside.

Authors:  A Hageboutros; G R Hudes; J Brennan; F Green; J Hoffman; F P LaCreta; J Colofiore; D S Martin; R F Ozols; P J O'Dwyer
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.